Sphingosine 1-phosphate (S1P), a lysosphingolipid associated with high-density lipoprotein (HDL), contributes to the anti-atherogenic potential attributed to this lipoprotein. This study examined whether a reduction of S1P plasma levels affects atherosclerosis in a murine model of disease. LDL-R-/-mice on Western diet were given ABC294640, an inhibitor of sphingosine kinase (SphK) for 16 weeks. ABC294640 decreased plasma S1P by approximately 30%. However, ABC294640 failed to affect atherosclerotic lesion formation. Plasma triglycerides were reduced whereas total and HDL-cholesterol remained unchanged in course of ABC294640 treatment. ABC294640 increased plasma interleukin (IL)-12p70 and RANTES concentration as well as IL-12p70, RANTES and interferon (IFN)-γ production by peritoneal cells and this was paralleled by enhanced activity of peritoneal and spleen dendritic cells as evidenced by up-regulation of CD86 and MHC-II on CD11c+ cells. As a consequence, increased T-cell activation was noted in ABC294640-treated mice as indicated by enhanced CD4+ splenocyte proliferation, IFN-γ and IL-2 production, and CD69 expression. Concomitantly, however, ABC294640 treatment redistributed CD4+ and CD8+ cells from blood to lymphatic organs and reduced T-cell number within atherosclerotic lesions. In addition, plasma sVCAM-1, sICAM-1, and MCP-1 levels as well as in vivo leukocyte adhesion and CCL19-induced T-cell penetration into peritoneum were lower in ABC294640-treated animals. In vitro experiments demonstrated reduced VCAM-1 and ICAM-1 expression and lymphocyte adhesion to endothelial cells exposed to ABC294640. In conclusion, treatment with SphK inhibitor leads to both pro- and anti-atherogenic effects in LDL-R-/- mice. As a consequence, SphK inhibition fails to affect atherosclerosis despite significant S1P reduction in plasma.
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R-/-) mice / Poti', Francesco; M., Bot; Costa, Sara; Bergonzini, Valeria; L., Maines; G., Varga; H., Freise; H., Robenek; Simoni, Manuela; Nofer, JERZY ROCH. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - ELETTRONICO. - 107:(2012), pp. nd-nd. [10.1160/TH11-08-0583]
Data di pubblicazione: | 2012 | |
Titolo: | Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R-/-) mice. | |
Autore/i: | Poti', Francesco; M., Bot; Costa, Sara; Bergonzini, Valeria; L., Maines; G., Varga; H., Freise; H., Robenek; Simoni, Manuela; Nofer, JERZY ROCH | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1160/TH11-08-0583 | |
Rivista: | ||
Volume: | 107 | |
Pagina iniziale: | nd | |
Pagina finale: | nd | |
Codice identificativo ISI: | WOS:000302495200020 | |
Codice identificativo Scopus: | 2-s2.0-84857753699 | |
Codice identificativo Pubmed: | 22234485 | |
Citazione: | Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R-/-) mice / Poti', Francesco; M., Bot; Costa, Sara; Bergonzini, Valeria; L., Maines; G., Varga; H., Freise; H., Robenek; Simoni, Manuela; Nofer, JERZY ROCH. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - ELETTRONICO. - 107:(2012), pp. nd-nd. [10.1160/TH11-08-0583] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
137.pdf | Articolo principale | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris